Clinical Trial Data for TCM Adjuvant Therapy in Stage IB-IIIA NSCLC Patients

A dataset from a multi-center, randomized, double-blind, placebo-controlled trial involving 286 patients with completely resected stage IB-IIIA non-small cell lung cancer. The data, published by Liping Shen on figshare, compares disease-free survival and quality-of-life outcomes between a group receiving comprehensive Traditional Chinese Medicine with chemotherapy and a control group. The trial was conducted at four centers in Shanghai, China.

Use Cases

• Compare disease-free survival (DFS) outcomes between treatment groups based on the reported 37.8 vs. 31.6 month median DFS.
• Analyze trends in 2-year DFS rates (65.70% vs. 55.4%) for statistical significance.
• Evaluate the impact of TCM on patient-reported quality-of-life metrics like fatigue, pain, and physical function.
• Assess treatment safety profiles by examining reported adverse events from the trial.

Strengths

• Data originates from a randomized, double-blind, placebo-controlled trial, a rigorous study design.
• Includes results from 286 participants, providing a substantive sample size for analysis.
• Reports specific clinical outcomes including median DFS (37.8 months), hazard ratios (0.73), and p-values (0.045).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to its collection from four centers in Shanghai.

Provenance

Source

Liping Shen via figshare.

Collection Method

Data collected from a multi-center, randomized, double-blind, placebo-controlled clinical trial.

Time Range

Temporal coverage of the trial is not specified.

Freshness

Last updated 2026-04-09 07:40:47; freshness should be verified.

Geography

Data was collected at four clinical centers in Shanghai, China.